newwin
Luciann Nguyen
Settings
← Accounts
biotech

GeneCraft Inc.

48
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

GeneCraft Inc.

New trial — Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

New trialNCT06934590
48/100
Opportunity
Commercial fit6/25
Clinical timing20/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1 trial NCT06934590 posted by GeneCraft Inc.: "Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC". New trial on a phase 1 not yet recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 503 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT06934590
Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC
phase 1
mol. elig.